ALOGLIPTIN-METFORMIN 12.5-500

What it is

ALOGLIPTIN-METFORMIN 12.5-500 is how the CMS NADAC file names this product. The FDA NDC Directory lists it as alogliptin and metformin hydrochloride.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Padagis Israel Pharmaceuticals Ltd.

FDA lists it under 2 Established Pharmacologic Classes: Biguanide and Dipeptidyl Peptidase 4 Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 45802-0169-72.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $69.62 for 30 tablets (30 × $2.3206 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

What NADAC measures · Why 30 tablets · NADAC explanation codes

The NDC

• 45802-0169-72 · Padagis Israel Pharmaceuticals Ltd · $2.3206 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name alogliptin and metformin hydrochloride with ALOGLIPTIN-METFORMIN 12.5-500.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $2.3206 per EA filed.

Of the 71 other products in FDA’s Biguanide class priced per EA, 49 have a higher middle NADAC price and 22 a lower one. The one in the middle is SYNJARDY XR 5-1,000 MG TABLET, at $5.61111 per EA filed (eff. 2026-09-23).

Of the 43 other products in FDA’s Dipeptidyl Peptidase 4 Inhibitor class priced per EA, 39 have a higher middle NADAC price and 4 a lower one. The one in the middle is TRIJARDY XR 12.5-2.5-1,000 MG, at $5.62766 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $78.35 for 30 tablets, at an average of $2.61155 per EA in 2024 (2024-01-01 to 2024-12-31) for “Alogliptin-Metformin” and “Alogliptin Benz/Metformin HCl”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 6,563 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.